Evommune, Inc.

Evommune, Inc. (EVMN) priced its initial public offering on Nov 6, 2025 at $16.00 per share, within its $15.00–$17.00 range, raising $150M, and listed on NYSE. At the IPO price its market capitalization was about $481.2M. Morgan Stanley was lead-left underwriter, joined by Leerink Partners, Evercore ISI and Cantor. Cooley advised the company and Covington & Burling advised the underwriters.

Evommune, Inc. is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Its initial clinical programs focus on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis.

Status

IPO

Ticker

EVMN

Exchange

NYSE

Priced

Nov 6, 2025

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$150M

Market cap at IPO price

$481.2M

First filed

Oct 9, 2025

Underwriters

Morgan Stanley, Leerink Partners, Evercore ISI and Cantor

Company counsel

Cooley

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.